Movement Disorders in Multiple Sclerosis Patients

Multiple Sclerosis Clinical Trial

Official title:

Clinical and Radiological Evaluation of Movement Disorders in Multiple Sclerosis Patients.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05973929
• Other study ID #: Neuro-Med._0000044
• Status: Recruiting
• Start date: September 22, 2022
• Est. completion date: May 1, 2024

Study information

• Verified date: August 2023
• Source: Al-Azhar University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to determine the prevalence of movement disorders in MS patients.

Also,To know the clinical type of movement disorders occurring with multiple sclerosis patients and the MRI finding of those patients. Moreover, to find the correlation between the movement disorder and the different types of MS.

Description:

A randomized cross-sectional study will be conducted on diagnosed multiple sclerosis patients who were diagnosed according to McDonald criteria of MS 2017 (Thompson et al. 2018).

The investigators will study the prevalence of movement disorders in M.S patients, clinical type of movement disorder and the MRI findings. Data collected from patients admitted or following at Al-Azhar university hospitals at Al-Hussein and El-Sayed Galal hospitals. The included eligible patients should fulfil the following inclusion criteria:

i. Full clinical history and neurological assessment. ii. Detailed multiple sclerosis history according to MS unit history sheet. iii. Detailed history of movement disorder which include clinical type of movement disorder and medication taken (or not).

iv. MRI Brain and spine of the included patient will be photographed.

Exclusion criteria:

1. Patients with multiple sclerosis mimics which can cause movement disorders e.g., systemic disease or overlap syndromes including systemic lupus, vasculitis, hepatic failure, renal failure, hyperthyroidism, electrolyte disturbances, Behcet's disease or CNS infection.

2. patients with primary movement disorders or related to other neurodegenerative diseases.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 57
• Est. completion date: May 1, 2024
• Est. primary completion date: March 21, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• We will study the prevalence of movement disorders in M.S patients, clinical type of movement disorder and the MRI findings. Data collected from patients admitted or following at Al-Azhar university hospitals at Al-Hussein and El-Sayed Galal hospitals. The included eligible patients should fulfil the following inclusion criteria: i. Full clinical history and neurological assessment. ii. Detailed multiple sclerosis history according to MS unit history sheet. iii. Detailed history of movement disorder which include clinical type of movement disorder and medication taken (or not).

iv. MRI Brain and spine of the included patient will be photographed.

Exclusion Criteria:

• 1-Patients with multiple sclerosis mimics which can cause movement disorders e.g., systemic disease or overlap syndromes including systemic lupus, vasculitis, hepatic failure, renal failure, hyperthyroidism, electrolyte disturbances, Behcet's disease or CNS infection.

2-patients with primary movement disorders or related to other neurodegenerative diseases.

Related Conditions & MeSH terms

• Movement Disorders
• Multiple Sclerosis
• Sclerosis

Intervention

Other:
• Screen for movement disorder and correlates it with MRI findings.
To determine the prevalence of movement disorders in MS patients. To know the clinical type of movement disorders occurring with multiple sclerosis patients and the MRI finding of those patients. To find the correlation between the movement disorder and the different types of MS.

Locations

Country	Name	City	State
Egypt	Mostafa Mahmoud Hassan Meshref	Cairo	Select A State Or Province

Sponsors (1)

Lead Sponsor	Collaborator
Al-Azhar University

Country where clinical trial is conducted

Egypt, 

References & Publications (14)

Abboud H, Yu XX, Knusel K, Fernandez HH, Cohen JA. Movement disorders in early MS and related diseases: A prospective observational study. Neurol Clin Pract. 2019 Feb;9(1):24-31. doi: 10.1212/CPJ.0000000000000560. — View Citation

Calabresi PA. Diagnosis and management of multiple sclerosis. Am Fam Physician. 2004 Nov 15;70(10):1935-44. — View Citation

Cameron MH, Nilsagard Y. Balance, gait, and falls in multiple sclerosis. Handb Clin Neurol. 2018;159:237-250. doi: 10.1016/B978-0-444-63916-5.00015-X. — View Citation

Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015 Sep 15;15(9):545-58. doi: 10.1038/nri3871. Epub 2015 Aug 7. — View Citation

Deuschl G. Movement disorders in multiple sclerosis and their treatment. Neurodegener Dis Manag. 2016 Dec;6(6s):31-35. doi: 10.2217/nmt-2016-0053. — View Citation

Fragoso YD, Araujo MG, Branco NL. Kinesigenic paroxysmal hemidyskinesia as the initial presentation of multiple sclerosis. MedGenMed. 2006 Oct 4;8(4):3. — View Citation

GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 Mar;18(3):269-285. doi: 10.1016/S1474-4422(18)30443-5. — View Citation

Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J; MSCOI Study Group; European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017 Jul;23(8):1123-1136. doi: 10.1177/1352458517694432. Ep — View Citation

Mehanna R, Jankovic J. Movement disorders in multiple sclerosis and other demyelinating diseases. J Neurol Sci. 2013 May 15;328(1-2):1-8. doi: 10.1016/j.jns.2013.02.007. Epub 2013 Mar 19. — View Citation

Nociti V, Bentivoglio AR, Frisullo G, Fasano A, Soleti F, Iorio R, Loria G, Patanella AK, Marti A, Tartaglione T, Tonali PA, Batocchi AP. Movement disorders in multiple sclerosis: Causal or coincidental association? Mult Scler. 2008 Nov;14(9):1284-7. doi: — View Citation

Oakes PK, Srivatsal SR, Davis MY, Samii A. Movement disorders in multiple sclerosis. Phys Med Rehabil Clin N Am. 2013 Nov;24(4):639-51. doi: 10.1016/j.pmr.2013.06.003. Epub 2013 Aug 27. — View Citation

Suarez-Cedeno G, Mehanna R. Movement Disorders in Multiple Sclerosis and Other Demyelinating Diseases: A Retrospective Review From a Tertiary Academic Center. Neurologist. 2021 Sep 7;26(5):161-166. doi: 10.1097/NRL.0000000000000333. — View Citation

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintore M, Trab — View Citation

Waubant E, Alize P, Tourbah A, Agid Y. Paroxysmal dystonia (tonic spasm) in multiple sclerosis. Neurology. 2001 Dec 26;57(12):2320-1. doi: 10.1212/wnl.57.12.2320. No abstract available. — View Citation

* Note: There are 14 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the prevalence of movement disorders in MS patients.	To know the percentage of occurance of movement disorders in MS patients.	Through study completion, an average of 1.5 year
Primary	know the clinical type of movement disorders occurring with multiple sclerosis patients and the MRI finding of those patients.	To know the specific semiology for each movement disorder.	Through study completion, an average of 1.5 year
Primary	find the correlation between the movement disorder and the different types of MS.	To know if there is a correlation between the movement disorder and the different types of MS.	Through study completion, an average of 1.5 year